Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

-
September 21, 2018
Spago Nanomedical

Improved early detection of breast cancer with MRI compared to mammography in high-risk women

A prospective American study recently published in Clinical Cancer Research shows that bi-annual screening with MRI performs better than mammography for the detection of breast tumors in women who are at high-risk of developing disease based on genetics. This is particularly evident in women who carries the mutation BRCA1 (Guindalini et al., DOI: 10.1158/1078-0432.CCR-18-0200).

Improved early detection of breast cancer with MRI compared to mammography in high-risk women

A prospective American study recently published in Clinical Cancer Research shows that bi-annual screening with MRI performs better than mammography for the detection of breast tumors in women who are at high-risk of developing disease based on genetics. This is particularly evident in women who carries the mutation BRCA1 (Guindalini et al., DOI: 10.1158/1078-0432.CCR-18-0200).

-
Spago Nanomedical
-
September 21, 2018

A prospective American study recently published in Clinical Cancer Research shows that bi-annual screening with MRI performs better than mammography for the detection of breast tumors in women who are at high-risk of developing disease based on genetics. This is particularly evident in women who carries the mutation BRCA1 (Guindalini et al., DOI: 10.1158/1078-0432.CCR-18-0200).

The recall rate due to false positive diagnoses with MRI was lower in the current study compared to previous ones. The relatively high rate of false positives compared to other imaging modalities is nevertheless a limiting factor for the use of MRI. A tumor selective contrast agent with high signal strength (relaxivity)may provide increased specificity in MRI-diagnoses and could open the door for MRI as a routine method for screening and surveillance of women at increased risk of developing breast cancer and also for imaging in other cancer indications.

Last updated:
September 21, 2018

Spago Nanomedical

Spago Nanomedical AB is a Swedish company performing research and development within nanomedicine. Focus is the development of nanomaterials for tumor diagnostics and treatment of cancer. The main development projects SpagoPix and Tumorad are both built on proprietary nanomaterials

Click here to read more about us!
Get in touch with us!
Visit us

Scheelevägen 22
SE-223 63 Lund
Sweden

Send us mail

A prospective American study recently published in Clinical Cancer Research shows that bi-annual screening with MRI performs better than mammography for the detection of breast tumors in women who are at high-risk of developing disease based on genetics. This is particularly evident in women who carries the mutation BRCA1 (Guindalini et al., DOI: 10.1158/1078-0432.CCR-18-0200).

The recall rate due to false positive diagnoses with MRI was lower in the current study compared to previous ones. The relatively high rate of false positives compared to other imaging modalities is nevertheless a limiting factor for the use of MRI. A tumor selective contrast agent with high signal strength (relaxivity)may provide increased specificity in MRI-diagnoses and could open the door for MRI as a routine method for screening and surveillance of women at increased risk of developing breast cancer and also for imaging in other cancer indications.

Last updated:
September 21, 2018

Spago Nanomedical

Spago Nanomedical AB is a Swedish company performing research and development within nanomedicine. Focus is the development of nanomaterials for tumor diagnostics and treatment of cancer. The main development projects SpagoPix and Tumorad are both built on proprietary nanomaterials

Click here to read more about us!
Get in touch with us!
Visit us

Scheelevägen 22
SE-223 63 Lund
Sweden

Send us mail